Lanlan Pang1, Zefu Liu2, Sheng Lin3, Zhidong Liu4, Hengyu Liu4, Zihang Mai4, Zhuowei Liu2, Chongxiang Chen5, Qingyu Zhao6. 1. Department of Intensive Care Unit, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, China. 2. Department of Urology, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, China. 3. Department of pulmonary and critical care medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian, China. 4. Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong Province, China. 5. Department of Intensive Care Unit, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Dongfeng East Road 651, Guangzhou 510060, China. 6. Department of Intensive Care Unit, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou 510060, China.
Abstract
BACKGROUND AND AIMS: Lung cancer patients suffer from deterioration in their physical and psychological function, which exerts a negative influence on their quality of life (QOL). Telemedicine has been proven to be an effective intervention for patients with several chronic diseases. The aim of this systematic review and meta-analysis was to investigate the efficacy of telemedicine in improving QOL in lung cancer patients. METHODS: PubMed, Cochrane Library, EMBASE, Web of Science and Scopus databases were searched for randomized controlled trials that investigated the effectiveness of telemedicine in lung cancer patients. Review Manager 5.3 and Stata 15.1 were used to perform data analysis. RESULTS: Our meta-analysis included eight clinical trials with a total of 635 lung cancer patients. The results showed that the telemedicine group had significantly higher QOL than the usual care group [standard mean difference (SMD) 0.96, 95% confidence interval (CI) 0.29-1.63, I 2 = 91%]. In addition, the telemedicine group had lower anxiety (SMD -0.44, 95% CI -0.66 to -0.23, I 2 = 3%) and depression scores (SMD -0.48, 95% CI -0.91 to -0.05, I 2 = 66%) than the usual care group. However, no significant differences were found in fatigue and pain outcomes between the two groups. CONCLUSION: Telemedicine may be an effective method of improving QOL in lung cancer patients and the further development and use of telemedicine care is recommended.
BACKGROUND AND AIMS: Lung cancer patients suffer from deterioration in their physical and psychological function, which exerts a negative influence on their quality of life (QOL). Telemedicine has been proven to be an effective intervention for patients with several chronic diseases. The aim of this systematic review and meta-analysis was to investigate the efficacy of telemedicine in improving QOL in lung cancer patients. METHODS: PubMed, Cochrane Library, EMBASE, Web of Science and Scopus databases were searched for randomized controlled trials that investigated the effectiveness of telemedicine in lung cancer patients. Review Manager 5.3 and Stata 15.1 were used to perform data analysis. RESULTS: Our meta-analysis included eight clinical trials with a total of 635 lung cancer patients. The results showed that the telemedicine group had significantly higher QOL than the usual care group [standard mean difference (SMD) 0.96, 95% confidence interval (CI) 0.29-1.63, I 2 = 91%]. In addition, the telemedicine group had lower anxiety (SMD -0.44, 95% CI -0.66 to -0.23, I 2 = 3%) and depression scores (SMD -0.48, 95% CI -0.91 to -0.05, I 2 = 66%) than the usual care group. However, no significant differences were found in fatigue and pain outcomes between the two groups. CONCLUSION: Telemedicine may be an effective method of improving QOL in lung cancer patients and the further development and use of telemedicine care is recommended.
Lung cancer is one of the most common types of cancers and the leading cause of death
from malignancy. At least 2.09 million people were newly diagnosed with lung cancer
and the number of cancer-related deaths had reached up to 1.76 million in 2018
worldwide.[1,2]
The characteristics of tumour cells and certain cancer-related treatments are such
that patients with lung cancer endure a high burden of symptoms such as fatigue and
anxiety.[3,4]
As a result, preserving the quality of life (QOL) of patients as they decline has
become an urgent concern.[5-7]Telemedicine was defined by the World Health Organization (WHO) in 1997 as the
delivery of health care services by information and communication technologies
(ICTs) at a distance.[8] Recommended as a type of safe, cost-effective and time-saving intervention,
it has emerged in the last two decades as a non-invasive surveillance and follow-up
method for patients discharged from hospital.[9,10] ICTs such as websites,
telephone and telemedicine systems have been established to detect and manage
patients’ physical and psychological changes in a timely manner, improve
communication between health care providers and patients or their families and allow
patients to effectively self-manage.[11,12] In addition, the value of
telemedicine in chronic disease management has been confirmed in meta-analyses
examining its use in conditions such as heart failure, chronic obstructive pulmonary
disease and asthma.[13-15] Telemedicine
has been proven to have played an important role in dermatology during the 2019
novel coronavirus disease (COVID-19) pandemic.[16]Few reviews have explored the effectiveness of telehealth in the management of
malignant tumours, especially in improving QOL. In the past few years, several
clinical trials have been conducted to examine the effectiveness of telemedicine in
increasing the QOL of lung cancer patients, and mobile applications have even been
developed to monitor their disease status.[17-21] On the one hand, patients
diagnosed with lung cancer demand an effective intervention to enable them to manage
problems under their own initiative on a long-term basis in the follow-up period
after initial treatment. On the other hand, interaction between health care
providers and lung cancer patients has been a target for improving patients’ QOL.[22] Telemedicine is acknowledged as a promising method for improving QOL by
virtue of its unique advantages, and the results of several clinical trials have
provided strong evidence for this view.[23,24] However, due to high
heterogeneity among these studies, the exact effect of telemedicine on the QOL of
patients with lung cancer remains unknown. Thus, we conducted this meta-analysis to
examine the superiority of telemedicine in lung cancer patients.
Methods
Search strategy
Two investigators (LP and ZL) independently searched for articles in the
databases PubMed, Cochrane library, EMBASE, Web of Science and Scopus. Medical
Subject Headings (MeSH) and free search terms were both used in the literature
search. The search terms included telemedicine, telemonitor, e-health,
telehealth, telecommunication, telemanagement, telecare, telephone monitoring,
telepathology, remote and short message service, mobile health,
telerehabilitation, lung neoplasm, lung neoplasms, lung carcinoma, lung cancer
and lung tumour. The search strategy used for PubMed was as follows:
(telemedicine OR telemonitor OR e-health OR telehealth OR telecommunication OR
telemanagement OR telecare OR telephone monitoring OR telepathology OR remote
and short message service OR mobile health OR telerehabilitation) AND (lung
neoplasm OR lung neoplasms OR lung carcinoma OR lung cancer OR lung tumour). The
final search date was 14 February 2020. In addition, we manually searched the
references of the screened articles for further high-quality studies.
Study selection
Two investigators (LP and HL) independently skimmed the identified abstracts and
selected articles to fully review. The same two investigators independently
undertook full text review (including intensively reading appropriate articles
after skimming the references of screened articles). A senior investigator (CC)
adjudicated when eligibility could not be agreed.Inclusion criteria were as follows: (1) patients diagnosed with lung cancer; (2)
telemedicine intervention, defined as “the use of telecommunication systems to
deliver health care at a distance”; (3) usual care referred to the usual
oncology care; (4) reported outcomes including at least one of the following:
QOL, anxiety, depression, fatigue or pain; (5) experimental studies, including
randomized controlled trials (RCTs) and quasi-RCTs.The following were excluded: (1) letters or reviews; (2) laboratory studies, case
reports or animal experimental studies; (3) studies not published in English
language; (4) studies with an absence of key information such as sample
size.
Data extraction and outcome definitions
Two investigators (LP and HL) independently extracted data and any disagreements
were discussed with the third investigator (ZL) or subsequently resolved
via consensus. Extracted data included first author,
publication year and country, number of participants and their characteristics
(age, sex and disease status), interventions (technology, intervention
providers), follow-up time and outcomes. If the necessary data could not be
found in the published paper, investigators obtained them by emailing the
original authors.QOL was set as our primary outcome, with anxiety, depression score, fatigue and
pain as secondary outcomes.
Risk of bias assessment
Two investigators (LP and HL) independently undertook a risk of bias assessment
and any doubts were resolved by the third investigator (ZL).We evaluated risk of bias of trials according to the Cochrane handbook of
systematic reviews of interventions (http://handbook.cochrane.org). In addition, we applied the
revised Jadad’s scale to assess the quality of each study.
Statistical analysis
Review Manager 5.3 (Cochrane) and Stata 15.1 were used for statistical analysis.
For continuous variables such as QOL, we calculated standardized mean difference
(SMD) with 95% confidence interval (CI). For discrete variables, we calculated
odds ratio with 95% CI. Heterogeneity was evaluated using the Cochrane
Q-statistic and I2 statistic. If the
I2 statistic was above 50% and the Cochrane
Q-statistic had a p value ⩽ 0.1, a random-effects model was
used. However, if no considerable heterogeneity among studies was apparent, a
fixed-effect model would be used. Subgroup analysis was conducted to explore
high heterogeneity and pre-defined stratification including the follow-up time,
type of QOL scale and technologies used. Funnel plots and Egger test were used
to assess potential publication bias.
Results
Search process, study characteristics and quality assessment
Based on the search criteria, we found 1742 articles. Of these, 1353 articles
remained after removing duplications. We selected 73 of the articles for full
consideration after reading the title and abstract. In addition, we manually
searched two studies for intensive reading after skimming the references lists
of the 73 articles. Finally, eight studies with a total of 635 patients were
enrolled to our meta-analysis, all of which were experimental studies (six RCTs
and two quasi-RCTs) published between 2014 and 2019.[23-30] The process of selecting
the included studies is presented in Figure 1.
Figure 1.
Flow diagram of the selection of the included studies.
Flow diagram of the selection of the included studies.Table 1 shows the
basic characteristics of the enrolled articles and the essential information of
the participants. The studies were conducted in United States,[23,26,27]
China,[28,30] United Kingdom,[29] France[24] and Turkey.[25] Six[23,25-27,29,30] of them
had adopted a telephone-based intervention while the remaining studies were
Web-based. Follow-up duration ranged from 3 weeks to 8 months. Scales to measure
QOL included the WHO-QOL score and the Functional Living Index − Cancer, among
others. Revised Jadad’s scale scores of the included studies are also presented
in Table 1, and
indicate that the studies were of high quality except for two. Figures 2 and 3 demonstrate the
methodological quality of the included studies. In the domain of incomplete
outcome data and selective reporting, all the included studies were judged as
having low risk of bias. However, two studies (quasi-RCTs)[23,25] failed to
meet the criteria of random sequence generation and allocation concealment.
Whether blinding was carried out was unclear in most of the studies.
Table 1.
Characteristics of the included studies and participants.
First author
Country
Age* (years)
Patients, number*
Jadad’s score
Patients’ characteristics
Intervention*
Contact
Technology
Follow-up
Outcomes and outcome measures
Badr[27]
United States
68.17 ± 10.30 (average of all patients)
20 versus 19
1+1+1+1 = 4
Advanced LC patients who were within 1 month of treatment
initiation
Telephone-based dyadic psychosocial intervention
versus usual care
Mental health interventionist
Telephone
6 weeks
Depression, anxiety (the six-item PROMIS short-form
depression and anxiety measure)
Chang[30]
Taiwan, China
62.00 ± 12.15 versus 58.39 ± 13.39
32 versus 33
1+1+1+1 = 4
LC patients recovering from lung lobectomy
Usual care plus once-daily additional brisk walking exercise
and weekly telephone calls through week 12
versus usual care
Researcher
Telephone
6 months
QOL [WHO QOL-BREF (Taiwanese)]
Chen[23]
United States
63 ± 8.9 versus 63 ± 11.3
26 versus 21
0+0+1+1 = 2
LC patients in Appalachia
Wireless home-telemonitoring system, patient-centred phone
coaching in addition to usual post-discharge care
versus usual post-discharge care
Nurse
Telephone
2 months
QOL (WHO-5)
Denis[24]
France
65.2 (35.7–86.9) versus 64.3
(42.7–88.1)
60 versus 61
2+2+1+1 = 6
Advanced-stage LC patients
A Web-mediated follow-up algorithm (experimental arm) based
on weekly self-scored patient symptoms
versus routine follow-up with
computerized tomography scan (usual care)
Oncologist
Website
6 months
Quality of life (FACT-L scores)
Hintistan[25]
Turkey
⩽49 years 8 versus 750–59 years 15
versus 8⩾60 years 7
versus 15
30 versus 30
0+0+1+1 = 2
LC patients in the Ambulatory Chemotherapy Unit
The standard care plus follow-up call within a week after
each chemotherapy session versus standard
care
Nurse
Telephone
3 weeks
QOL (FLIC)
Huang 28
Taiwan, China
61.00 ± 2.04 versus 58.68 ± 1.77
27 versus 28
2+1+1+1 = 5
Patients receiving chemotherapy during the first 3 months
after initial diagnosis of advanced NSCLC
A Web-based health education programme allowing patients to
learn symptom management strategies biweekly
versus usual care
Nurse
Website
3 months
QOL (EORTC C30)
Mosher[26]
United States
63.47 ± 7.68 versus 61.96 ± 8.20
51 versus 55
2+2+2+1 = 7
Symptomatic LC patients
Telephone-based symptom management consisting of
cognitive–behavioural and emotion-focused therapy
versus education/support condition
(usual care)
Licensed clinical social workers
Telephone
6 weeks
Depression, anxiety, fatigue (The Patient Health
Questionnaire-8, GAD-7, Fatigue Symptom Inventory)
Walker[29]
United Kingdom
63.6 ± 8.8 versus 63.9 ± 8.7
68 versus 74
2+2+2+1 = 7
Patients with LC and major depression
Depression care including telephone monitoring care
versus usual care
Nurse, psychiatrist
Telephone
8 months
QOL (EORTC-QLQ-C30), depression (SCL-20), anxiety
(SCL-10)
These items were recorded as experimental versus
control group.
EORTC, European Organization for Research and Treatment of Cancer;
FLIC, Functional Living Index-Cancer; GAD-7, Generalized Anxiety
Disorder seven-item; LC, lung cancer; NSCLC, non-small cell lung
cancer; PROMIS, Patient Reported Outcomes Measurement Information
System; QOL, quality of life; SCL, Symptom Checklist; WHO, World
Health Organization; WHO QOL-BREF, World Health Organization Quality
of Life Questionnaire, brief version; FACT-L, Functional Assessmet
of Cancer Therapy-lung.
Figure 2.
Risk of bias graph.
Figure 3.
Risk of bias summary.
Characteristics of the included studies and participants.These items were recorded as experimental versus
control group.EORTC, European Organization for Research and Treatment of Cancer;
FLIC, Functional Living Index-Cancer; GAD-7, Generalized Anxiety
Disorder seven-item; LC, lung cancer; NSCLC, non-small cell lung
cancer; PROMIS, Patient Reported Outcomes Measurement Information
System; QOL, quality of life; SCL, Symptom Checklist; WHO, World
Health Organization; WHO QOL-BREF, World Health Organization Quality
of Life Questionnaire, brief version; FACT-L, Functional Assessmet
of Cancer Therapy-lung.Risk of bias graph.Risk of bias summary.
Quality of life
To compare telemedicine with usual care in the improvement of QOL, we enrolled
data from six of the studies[23-25,28-30] with a total of 490
patients. The results demonstrated that the telemedicine group reported a
significantly higher QOL than the usual care group (SMD 0.96, 95% CI 0.29–1.63).
Heterogeneity testing showed that I2 = 91%,
indicating high heterogeneity (Figure 4). To address high heterogeneity, we conducted a subgroup
analysis grouped by follow-up time (>3 months or not), type of scale (WHO-QOL
or not) and type of technology (telephone-based or Web-based).
Figure 4.
Analysis comparing telemedicine versus usual care for
quality of life in lung cancer patients.
CI, confidence interval; IV, inverse variance; Std., standardized
Analysis comparing telemedicine versus usual care for
quality of life in lung cancer patients.CI, confidence interval; IV, inverse variance; Std., standardizedThe subgroup analysis for follow-up time showed that the telemedicine group had
significantly higher QOL than the usual care group for long-term follow-up (SMD
0.43, 95% CI 0.21–0.65, I2 = 0%), whereas no
significant difference was observed in short-term follow-up (SMD 1.67, 95%CI
−0.23 to 3.57, I2 = 96%; Figure 5).
Figure 5.
Subgroup analysis of quality of life comparing telemedicine with usual
care grouped by follow-up time.
CI, confidence interval; IV, inverse variance; Std., standardized
Subgroup analysis of quality of life comparing telemedicine with usual
care grouped by follow-up time.CI, confidence interval; IV, inverse variance; Std., standardizedIn the subgroup analysis for type of scale, the telemedicine group had
significantly higher QOL than the usual care group both in the WHO-QOL group
(SMD 0.46, 95% CI 0.08–0.83, I2 = 0%) and the other
types of QOL scale subgroup (SMD 1.26, 95% CI 0.25–2.28,
I2 = 95%; Figure 6).
Figure 6.
Subgroup analysis of quality of life comparing telemedicine with usual
care grouped by type of scale.
CI, confidence interval; IV, inverse variance; Std., standardized
Subgroup analysis of quality of life comparing telemedicine with usual
care grouped by type of scale.CI, confidence interval; IV, inverse variance; Std., standardizedIn the subgroup analysis stratified by type of technology, the telemedicine group
had significantly higher QOL than the usual care group for telephone-based
intervention (SMD 0.37, 95% CI 0.15–0.60, I2 = 0%).
However, differences between the Web-based and usual care groups were not
significant (SMD 2.40, 95%CI −1.15 to 5.95,
I2 = 98%; Figure 7).
Figure 7.
Subgroup analysis of quality of life comparing telemedicine with usual
care grouped by type of technology.
CI, confidence interval; IV, inverse variance; Std., standardized
Subgroup analysis of quality of life comparing telemedicine with usual
care grouped by type of technology.CI, confidence interval; IV, inverse variance; Std., standardizedThe funnel plot shown in Figure
8 indicates potential publication bias. However, no significant
potential publication bias was found using the Egger test
(p = 0.072). This inconsistency may be due to the small number
of enrolled studies.
Figure 8.
Funnel plot showing publication bias.
SE, standard error, SMD, standardized mean difference
Funnel plot showing publication bias.SE, standard error, SMD, standardized mean difference
Anxiety
To investigate the efficacy of telemedicine in alleviating anxiety compared with
usual care, we included four articles[25-27,29] with 347 patients. Anxiety
scores in the telemedicine group were lower than in the usual care group (SMD
−0.44, 95% CI −0.66 to −0.23). Heterogeneity testing showed that
I2 = 3%, indicating low heterogeneity (Figure 9).
Figure 9.
Analysis comparing telemedicine with usual care for managing anxiety in
lung cancer patients.
CI, confidence interval; IV, inverse variance; Std., standardized
Analysis comparing telemedicine with usual care for managing anxiety in
lung cancer patients.CI, confidence interval; IV, inverse variance; Std., standardized
Depression
Our study enrolled three studies[26,27,29] with a total of 287
patients to examine the superiority of telemedicine in easing depression in lung
cancer patients. As shown in Figure 9, depression scores were lower in the telemedicine group
than in the usual care group (SMD −0.48, 95% CI −0.91 to −0.05). Heterogeneity
testing showed that I2 = 66%, indicating high
heterogeneity (Figure
10).
Figure 10.
Analysis comparing telemedicine with usual care for managing depression
in lung cancer patients.
CI, confidence interval; IV, inverse variance; Std., standardized
Analysis comparing telemedicine with usual care for managing depression
in lung cancer patients.CI, confidence interval; IV, inverse variance; Std., standardized
Fatigue
To comparing telemedicine and usual care in relieving fatigue in lung cancer
patients, we enrolled three studies[25,26,29] with a total of 308
patients. The results indicated no significant difference between telemedicine
and usual care group in fatigue (SMD −0.27, 95% CI −0.85 to 0.30). Heterogeneity
testing showed that I2 = 83%, indicating high
heterogeneity (Figure
11).
Figure 11.
Analysis comparing telemedicine with usual care for managing fatigue in
lung cancer patients.
CI, confidence interval; IV, inverse variance; Std., standardized
Analysis comparing telemedicine with usual care for managing fatigue in
lung cancer patients.CI, confidence interval; IV, inverse variance; Std., standardized
Pain
To examine whether telemedicine could alleviate pain in lung cancer patients
compared with usual care, we included three studies[25,26,29] with a total of 308
patients. These two groups did not have significantly different pain outcomes
(SMD −0.18, 95% CI −0.57 to 0.21). Heterogeneity testing showed that
I2 = 64%, indicating high heterogeneity (Figure 12).
Figure 12.
Analysis comparing telemedicine with usual care for managing pain in lung
cancer patients.
CI, confidence interval; IV, inverse variance; Std., standardized
Analysis comparing telemedicine with usual care for managing pain in lung
cancer patients.CI, confidence interval; IV, inverse variance; Std., standardized
Discussion
With the further development of cancer treatment, clinic staff are increasingly
focused on not only patients’ lifespan but also their QOL. It is acknowledged that
patients with lung cancer experience a greater symptom burden than patients with any
other type of cancer.[4,7]
Previous studies have reported that lung cancer patients have severe symptoms,
including anxiety, depression, pain and fatigue.[3,7] Moreover, these symptoms have
been confirmed to exert a negative influence on their QOL.[31] Several studies have investigated the excellent capability of non-invasive
intervention to improve their QOL and alleviate their psychological
burden.[32-34] A
meta-analysis conducted by Chen et al.[35] demonstrated that telehealth care had advantages over usual care in improving
QOL in breast cancer patients, proving the positive effects of e-health technologies
in the management of malignancy.Our study explored the effectiveness of telemedicine on the management of patients
with lung cancer. We showed that a telemedicine group had a significantly better QOL
than a usual care group. Subgroup analysis stratified by type of technology
indicated that QOL in the telemedicine group was significantly better than that of
the usual care group when telephone-based intervention was used. Moreover, the
telemedicine group had a significantly better QOL than the usual care group during
long-term follow-up. The telemedicine group also had lower anxiety and depression
scores than the usual care group.One reason for these results about QOL is the unique superiority of telemedicine in
overcoming the obstacle of distance between patients and clinic staff. Follow-up
time was also subjected to subgroup analysis, with the results suggesting that
telemedicine might be more effective than usual care in the long-term management of
patients. This implies that the advantages of telehealth intervention over usual
care need a relatively long time to be observed. Compared with website-based
technology, lung cancer patients were more likely to benefit from telephone-based
interventions. As the lung cancer patient population is mostly elderly, the
assumption is that they may be more familiar with telephone technology than with the
internet.Lung cancer patients who undergo surgery spend a lot of time recovering from trauma
and with deteriorated pulmonary function.[36] Patients unfit for surgery may experience considerable discomfort and
distress during chemotherapy or radiotherapy.[37,38] Instant and ongoing feedback
from their physicians about their suffering may provide them with significant
comfort and support. Consequently, e-health web systems and applications have been
devised to ensure that clinic staff and patients can contact each other
conveniently, potentially contributing to improving patients’ QOL.[18,19] Nevertheless,
one RCT has reported that symptom telemonitoring combined with active feedback from
patients was not superior to the relatively passive method of symptom telemonitoring
only in maintaining the well-being of lung cancer patients.[39] This suggests further investigation and more research are necessary.In terms of symptom burden, anxiety and depression scales scores were lower in the
telemedicine group than those in the usual care group. However, there were no
significant differences in fatigue and pain outcomes between the two groups. Khue
et al.[40] has demonstrated that depression and anxiety pose risks to the QOL of lung
cancer patients, which is consistent with our findings. However, a telehealth-based
pulmonary rehabilitation intervention for advanced lung cancer patients was reported
to be capable of alleviating fatigue, depression and anxiety, which was not
completely concordant with our results.[20] In addition, an enrolled study conducted by Hintistan et al.[25] did not report the scales used for the assessment of pain and other
symptoms.The use of telemedicine to improve the QOL of lung cancer patients is relatively new
and the publication year of all our enrolled studies was 2014 or later. Chang
et al.[30] conducted an RCT in 2014 on an early postoperative walking exercise programme
in which the intervention was incorporated with a weekly telephone call. Since this,
a number of telehealth systems designed to maintain QOL in lung cancer patients have
emerged with technologies not limited to telephone but also including websites.
Therefore, more high-quality RCTs are encouraged to explore the promising value of
telemedicine in the maintenance of QOL in patients with lung cancer.Our study had some limitations. First, the number of enrolled articles and
participants was small, with recent clinical studies still underway. However, this
study was, to our knowledge, the first meta-analysis to investigate the efficacy of
telehealth care in lung cancer patients. Second, two of the enrolled studies were
quasi-RCTs that did not implement random sequence generation, impairing the quality
of this meta-analysis. Moreover, interventions in the telemedicine group were not
limited to only telephone or internet, but also incorporated other types of
non-invasive interventions, such as exercise programmes and depression care.
Finally, the form of interventions varied considerably among studies in terms of
follow-up time, technology medium and the intervention providers with whom patients
were in contact, leading to the high heterogeneity of the enrolled studies.
Conclusion
Overall, telemedicine has an advantage in improving the QOL and psychological
outcomes (including reported anxiety and depression) in patients with lung cancer.
Telemedicine may be an effective intervention in managing the well-being of lung
cancer patients. We suggest that more resources are put into the development of
telehealth care and more high-quality RCTs are conducted to explore the value of
telemedicine in the management of lung cancer patients.
Authors: Susan E Yount; Nan Rothrock; Michael Bass; Jennifer L Beaumont; Deborah Pach; Thomas Lad; Jyoti Patel; Maria Corona; Rebecca Weiland; Katherine Del Ciello; David Cella Journal: J Pain Symptom Manage Date: 2013-11-07 Impact factor: 3.612
Authors: Jane Walker; Christian Holm Hansen; Paul Martin; Stefan Symeonides; Charlie Gourley; Lucy Wall; David Weller; Gordon Murray; Michael Sharpe Journal: Lancet Oncol Date: 2014-08-27 Impact factor: 41.316
Authors: J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray Journal: Int J Cancer Date: 2018-12-06 Impact factor: 7.396
Authors: Kea Turner; Margarita Bobonis Babilonia; Cristina Naso; Oliver Nguyen; Brian D Gonzalez; Laura B Oswald; Edmondo Robinson; Jennifer Elston Lafata; Robert J Ferguson; Amir Alishahi Tabriz; Krupal B Patel; Julie Hallanger-Johnson; Nasrin Aldawoodi; Young-Rock Hong; Heather S L Jim; Philippe E Spiess Journal: J Med Internet Res Date: 2022-01-19 Impact factor: 5.428